The Nutrient – "Risolubles" – is Produced by "Nutracea" of Phoenix, Arizona
A very unique research will start at Hadassah soon.
Hadassah Physicians will try to find out to what extent a stabilized rice bran based nutrient, may affect the immune system of HIV/AIDS patients.
This clinical research will take about a year with 140 patients from the Hadassah AIDS Medicine Center participating.
The recruitment phase for the nutrient study is underway. The study will include 140 patients, some on anti retroviral drugs as well as those not taking such drugs to determine the effects of a 30gram daily dose of Risolubles from a nutritional and immunological standpoint. "Such a nutrient study will address an important topic in AIDS Medicine, the value of nutrients, and specifically stabilized rice bran, in boosting the immune function beyond what is achieved with anti-retroviral drugs," says Prof. Shlomo Maayan, Co Principle Investigator of the study, Director of the Hadassah Medical AIDS Center in Jerusalem.
"The randomized, controlled design of the NutraCea study will examine the effect of RiSolubles® compared to that of a placebo on patients’ immune status, well-being and other important parameters” says Prof. Allon Moses, Co-Principle Investigator and Chairman of the Dept. of Clinical Microbiology & Infectious Disease at Hadassah
“ We were strongly compelled to conduct a study of this nature based on years of anecdotal reports and recent reports from our feeding programs in Malawi and Central America. The reports suggested that people with HIV/AIDS were gaining weight, feeling more energetic and enjoying a better quality of life. In some patients, laboratory parameters suggested better immune function as well" said Margie Adelman, Senior Vice President of NutraCea. “ We believe our RiSolubles has concentrated doses of certain phyto nutrients that can possibly account for the testimonials that we are receiving. We know that the only way to prove it definitively was to engage in a clinical study that’s designed and performed at the highest medical standards.” Adelman added.
“We are very pleased to announce that our first human trial study is underway at a highly respected medical institution, renowned for its research in HIV/AIDS, and we hope to demonstrate a new, novel nutritional approach for millions of people around the world who
are suffering from HIV/AIDS” said Brad Edson, CEO and President of NutraCea.
For Further Information:
Prof. Shlomo Maayan, 050-7874327
Dr. Alon Mozes, 050-7874364
Yael Bossem-Levi, Spokesperson 050-5280597